Biotech venture firms are building companies around medicines originated in China and reaching exits far faster than the traditional model allows, according to a BioPharma Dive analysis published November 20. This year alone, three such startups, Ouro Medicines, Candid Therapeutics and, on Monday, Ollin Biosciences, have been acquired in billion dollar deals, and three more have priced initial public offerings, among them the obesity drugmaker Kailera Therapeutics. Ollin and Ouro were each acquired just over a year after their official launches.
The model inverts the usual venture sequence. Instead of incubating early research that takes many years to yield a drug, firms license Chinese assets that are already in or near human testing, build a United States company around them, and sell or list it once Western development begins. The approach depends on Chinese laboratories producing credible candidates faster and more cheaply than Western discovery, and on buyers paying for speed.
The cautionary case in the same analysis is Summit Therapeutics. Summit licensed ivonescimab from China’s Akeso and claimed in 2024 that it had beaten Merck’s Keytruda in a head to head trial run in China, sending its shares to all time highs. The drug has since succeeded in further trials and reached the market in China, but has not reproduced the standout result in a global study, analysts have questioned the reliability of some China only data, and this week the Food and Drug Administration refused Summit’s initial approval request in a form of lung cancer, as covered on this site on November 15. Summit’s shares have returned to levels last seen more than two years ago.
The two stories now run against each other. The fastest returns in biotech venture are coming from Chinese originated drugs, at the same moment as regulators discount China only evidence and lawmakers debate restricting the investment flow itself. Summit’s remaining hope, a frontline lung cancer study pitting ivonescimab plus chemotherapy against Keytruda plus chemotherapy, is the test of whether the model produces approved medicines or only quick exits.